Beth Sandy discusses the use of anti-psychotoci agent, olanzapine, when managing chemotherapy-induced nausea and vomiting (CINV).
Beth Sandy, CRNP, a nurse practitioner at the Abramson Cancer Center, Penn Medicine, discusses the use of the antipsychotic drug, olanzapine, as a treatment for chemotherapy-induced nausea and vomiting (CINV).
There have been recent advancements in other treatments for CINV, including work with NK1 and 5HT3 receptor antagonists. Recently, olanzapine has made it onto the NCCN guidelines for management of CINV. Despite the worry of sedation, this agent can be used as a preventive agent, and as needed. There are upcoming trials on the use of olanzapine in a triple regimen, in combination with the NK1 and 5HT3 receptor antagonists.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”